Compare LDI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LDI | RZLT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 954.8M | 1.0B |
| IPO Year | 2021 | N/A |
| Metric | LDI | RZLT |
|---|---|---|
| Price | $2.59 | $1.81 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $3.00 | ★ $12.33 |
| AVG Volume (30 Days) | 3.9M | ★ 9.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,095,780,000.00 | N/A |
| Revenue This Year | $24.99 | N/A |
| Revenue Next Year | $18.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.74 | N/A |
| 52 Week Low | $1.01 | $1.07 |
| 52 Week High | $5.05 | $11.46 |
| Indicator | LDI | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 22.97 |
| Support Level | $2.59 | $1.07 |
| Resistance Level | $2.88 | $11.17 |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | 0.01 | -0.81 |
| Stochastic Oscillator | 9.62 | 7.23 |
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.